Wenrui et al. (2023), in order to find a new therapeutic target for MF, constructed a DCM rat model by one-time intrabitoneal injection of 2%STZ, and found that Tongxinluo capsule may improve MF and myocardial structural disorders in DCM rats by inhibiting the expression of TGF-β1 protein. The gene discussed is TGFB1; the disease is familial dilated cardiomyopathy.